We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+3.27%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$259M
AUM Growth
+$35.4M
Cap. Flow
+$44.7M
Cap. Flow %
17.29%
Top 10 Hldgs %
86.99%
Holding
34
New
6
Increased
4
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$39M
2
ONC
BeOne Medicines Ltd
ONC
+$11.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$9.18M
5
MDCO
Medicines Co
MDCO
+$4.55M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.25M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$7.97M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$5.28M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.96M
5
HRTX icon
Heron Therapeutics
HRTX
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 80.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
26
DELISTED
Ignyta, Inc.
RXDX
$663K 0.26%
+125,000
New +$729K
NVET
27
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$578K 0.22%
154,840
– –
ONTXW
28
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$150K 0.06%
241,644
– –
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-100,000
Closed -$9.25M
CARM
30
DELISTED
Carisma Therapeutics
CARM
– –
-37,500
Closed -$2.1M
EPIX
31
DELISTED
ESSA Pharma
EPIX
– –
-1,405
Closed -$74K
HRTX icon
32
Heron Therapeutics
HRTX
$93.9M
– –
-200,000
Closed -$3.45M
RIGL icon
33
Rigel Pharmaceuticals
RIGL
$681M
– –
-135,114
Closed -$4.96M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Boxer Capital held 34 positions worth $259M, up 16% from $223M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Boxer Capital deployed $44.7M of net new capital in Q4 2016, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 250,000 shares worth $9.36M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $7.97M trimmed.

  • Boxer Capital's largest Q4 2016 buy was Alnylam Pharmaceuticals: 250,000 shares worth $9.36M.
  • Boxer Capital added most to AveXis, Inc. Common Stock in Q4 2016, an estimated $39M increase.
  • Boxer Capital's biggest Q4 2016 reduction was Seagen Inc. Common Stock, cutting an estimated $7.97M.
  • Boxer Capital fully exited BioMarin Pharmaceuticals in Q4 2016, selling an estimated $9.25M.
  • Boxer Capital's ten largest holdings make up 87% of its $259M portfolio in Q4 2016.
  • Boxer Capital opened 6 new positions and closed 6 in Q4 2016.
  • Boxer Capital's portfolio value rose 16% quarter-over-quarter to $259M.

Based on Boxer Capital's 13F filing for Q4 2016, filed 14 Feb 2017.